Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer
Investegate announcements from ProLynx LLC, ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially best-in-class
According to Coherent Market Insights, the global achondroplasia market is estimated to be valued at US$ 93.82 million in 2022 and is expected to exhibit a CAGR